Missed Butterfly Network's 262% Run? Here Is What Holders Saw

FDA clearance for Butterfly Network's blind sweep AI gestational age tool, able to estimate fetal age in about two minutes, gave investors a vivid proof point for its ultrasound on chip ambitions. Investors who held Butterfly Network over the past year are up 261.8%, including dividends. If you were weighing a purchase back on 2025-10-09, what conviction about future AI ultrasound adoption and licensing demand would have justified taking that risk?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

Butterfly Network is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.

The Two Butterfly Network Stories Investors Had To Choose Between

The shares cost US$2.57 at the start of the period, and anyone looking at Butterfly Network then had to choose between two very different stories.

The bullish narrative put fair value at US$3.19, based on confidence that Compass AI, HomeCare pilots and clinical AI apps would support recurring digital revenue linked to more accessible healthcare diagnostics.

The cautious view set fair value at US$2, emphasizing the risk that high R&D spending, slower enterprise deals and shrinking higher-margin software revenue could keep cash burn and dilution concerns front of mind.

What The Evidence Around Butterfly Network Actually Tested

Butterfly Network’s FDA clearance for its blind sweep gestational age tool, alongside Q2 2026 revenue of US$32.612 million and a net margin that moved to a loss of 39.6%, leaned toward the bullish case that AI ultrasound and licensing could scale. The shift still left profitability unproven, so the cautious worries about cash burn and execution risk stayed alive. The evidence cut both ways.

The whole episode turned on how quickly AI and licensing translated into higher quality revenue and better margins. For any other medtech stock with a similar pitch, a reader can track reported software or licensing sales and the direction of net margin to assess whether that story is actually playing out.

What Butterfly Network’s Price Now Assumes

Today Butterfly Network trades at US$8.25, and this Narrative’s Fair Value sits below that level. The writer focuses on ultrasound-on-chip licensing, Compass AI, and balance sheet strength as the core of the story.

The question now is what must keep going right. A buyer has to judge whether future funding needs stay limited without heavy dilution.

"The only reason that I didn't buy thousands of shares is the fact that many upstart companies dilute existing investor shares by offering more shares to the public to raise money. A silver lining to this is that it will most likely not happen here because this company has a strong balance sheet with no debt to equity and a 3-year cash runway, which would be long enough time for this company to be in profit land with no need to offer more shares."

The price and this Narrative do not agree. → Uncover what this Narrative says Butterfly Network is actually worth

Find Your Own Contrarian Opportunity

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

• Company 1 - 22% below our estimate - targets utility-scale solar arrays with integrated tracking, control software and hardware.
• Company 2 - 21% below our estimate - supplies digital investigation platforms that help process and analyse growing data volumes.
• Company 3 - 27% below our estimate - sells GPU-based systems to accelerate artificial intelligence workloads in large data centres.

Those are three of them. See the full list of 29 companies trading below our estimate →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com